Tanabe Mitsubishi Japan To File For Approval Of SGLT-2 Inhibitor Canagliflozin By Mid-2013
This article was originally published in PharmAsia News
Executive Summary
Tanabe Mitsubishi plans to file an application for approval of the SGLT-2 inhibitor canagliflozin in the first half of 2013.